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Various post-translational modifications (PTMs) regulate the localisation
and function of the multifunctional protein Annexin A2 (AnxA2). In
addition to its various tasks as a cytoskeletal- and membrane-associated
protein, AnxA2 can function as a trans-acting protein binding to cis-act-
ing sequences of specific mRNAs. In the present study, we have examined
the role of Ser25 phosphorylation in subcellular localisation of AnxA2
and its interaction with mRNP complexes. Subcellular fractionation and
confocal microscopy of rat neuroendocrine PC12 cells showed that Ser25-
phosphorylated AnxA2 (pSer25AnxA2) is absent from the nucleus and
mainly localised to the perinuclear region, evidently associating with both
membranes and cytoskeletal elements. Perinuclear targeting of AnxA2
was abolished by inhibition of protein kinase C activity, which resulted
in cortical enrichment of the protein. Although oligo(dT)-affinity purifica-
tion of mRNAs revealed that pSer25AnxA2 associates with nonpolyso-
mal, translationally inactive mRNP complexes, it displayed only partial
overlap with a marker of P-bodies. The phosphorylated protein is present
as high-molecular-mass forms, indicating that it contains additional cova-
lent PTMs, apparently triggered by its Ser25 phosphorylation. The subcel-
lular distributions of these forms clearly differ from the main form of
AnxA2 and are also distinct from that of Tyr23-phosphorylated AnxA2.
Immunoprecipitation verified that these high-molecular-mass forms are
due to ubiquitination and/or sumoylation. Moreover, these results indi-
cate that Ser25 phosphorylation and ubiquitin/SUMO1 conjugation of
AnxA2 promote its association with nonpolysomal mRNAs, providing
evidence of a possible mechanism to sequester a subpopulation of
mRNAs in a translationally inactive and transport competent form at a
distinct subcellular localisation.
As a multifunctional protein, Annexin A2 (AnxA2) is
involved in numerous processes including endo- and
exocytosis, actin dynamics and mRNA transport. It
also acts in DNA replication and repair, and most
likely also participates in transcription [1–7]. The dis-
tinction between the different cellular functions of
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AnxA2 is regulated by its post-translational modifica-
tions (PTMs), which determine its interaction with dif-
ferent ligands. The expression of AnxA2 is altered in
most cancers and its high expression is related to
neoangiogenesis and metastasis [8]. Therefore, to
understand the function of AnxA2 in various cellular
contexts, it is important to find out how the protein
discriminates between its multiple roles.
AnxA2 is likely to be present in larger protein com-
plexes, whose composition varies depending on their
function, localisation and PTMs [5,6,9]. The N termi-
nus of AnxA2 contains several major sites for PTMs
[2], including the phosphorylation sites Ser11 (counting
from the first Ser, as Met is removed in vivo), Ser25
and Tyr23, which can modify the structural and
functional properties of the protein [10–15]. Phospho-
rylation of Ser25 increases the accessibility of the
mRNA- and G-actin-binding sites of AnxA2 [16]. The
exposure of these sites most likely results from a
change in the position of the highly flexible N terminus
[16]. In addition, Ser25 phosphorylated AnxA2
(pSer25AnxA2) has been implicated in exocytosis
[13,17–20], macro-pinosome motility [21], recycling of
lipid rafts [22] and the recruitment of protein kinase C
(PKC) to phosphoinositide-4,5-biphosphate-rich mem-
brane domains [23]. Furthermore, PKC phosphoryla-
tion of Ser11 and Ser25 of AnxA2 dissociates the
(AnxA2-S100A10)2 tetramer, prevents the Tyr23 phos-
phorylation and subsequent translocation of AnxA2 to
the cell surface, and initiates the degradation of
S100A10 [24].
A cytoskeleton-associated pool of AnxA2 is sub-
jected to ubiquitination, indicating that this PTM
plays a role in intracellular targeting of AnxA2 and
most likely defines its specific function in this compart-
ment [25].
The Ser25 phosphorylation site is not readily
accessible to the solvent [16,26], suggesting that this
modification may be preceded by other PTMs or
ligand-binding events. The close proximity of the N
and C termini of AnxA2 raise the possibility that this
modification may involve the binding of PKC to the
14-3-3-like PKC-binding site in the very C terminus of
the protein [27] and/or its ubiquitination/sumoylation.
AnxA2 has been identified as both a cellular
mRNA- [28–34] and a viral RNA-binding protein [35].
Furthermore, its mRNA recognition motif has been
identified [5,32]. AnxA2 associates directly with a sub-
population of mRNAs in cytoskeleton-associated
mRNP complexes [28], including its cognate [31] and
c-myc [29,30] mRNAs. In both cases, AnxA2 binds to
a ~ 100 nucleotide region in the 30-untranslated regions
(UTRs) that appears to form a stem-loop structure
[30,31]. The protein has been implicated in mRNA
transport, based on its binding to the localisation ele-
ment present in the c-myc 30-UTR [30], which is
responsible for the targeting of this mRNA to the per-
inuclear region [36]. Although a number of mRNA-
binding proteins have been identified as components of
mRNP complexes, the organisation and regulation of
these complexes remain largely enigmatic. As these
complexes undergo dynamic compositional changes,
their protein–protein interactions are likely to be regu-
lated by PTMs. Interestingly, several proteins involved
in the assembly and nuclear export of mRNP com-
plexes are ubiquitinated, indicating that this PTM is
related to the mechanisms that regulate the spatio-tem-
poral dynamics of the maturing mRNP complexes
[37].
Here we present new evidence showing that Ser25-
phosphorylated high-molecular-mass forms of AnxA2
– which are also ubiquitinated and/or sumoylated –
associate with nonpolysomal mRNP complexes that
appear to be enriched in the perinuclear region of
PC12 cells. Furthermore, inhibition of PKC inhibits
the Ser25 phosphorylation of AnxA2 and prevents its
localisation to the perinuclear region and results in the
enrichment of AnxA2 at the inner cortical region of
the plasma membrane.
Results and discussion
Subcellular localisation of pSer25AnxA2
We previously showed that the phospho-mimicking
AnxA2-Ser25Glu mutant and AnxA2 Ser25 phospho-
rylated by PKC are not targeted to the nucleus. Fur-
thermore, the phospho-mimicking mutant displayed an
increased affinity for mRNA in vitro [16]. To further
address the subcellular localisation of pSer25AnxA2
and the functional significance of its ability to bind
mRNA, four different methods described in the Meth-
ods section were employed to fractionate PC12 cells
into the following subfractions (Fig. 1): cytoplasm
(lane 1), cytoplasm devoid of mitochondria (lane 2),
cytosol (lane 3), cytoskeleton (lane 4), endoplasmic
reticulum (ER; lane 5), mitochondria (lane 6), nucleus
(lane 7), as well as EGTA-released extracellular matrix
(ECM) proteins (lane 8). Samples from the various
fractions were subsequently subjected to 10% SDS/
PAGE and western blot analysis (Fig. 1). The present
experiments employ a pSer25AnxA2-specific antibody,
which recognises only the native AnxA2-Ser25Glu
mutant, but not the AnxA2-Ser25Asp mutant. This
indicates the specificity of the antibody, as well as sup-
ports the recognition of AnxA2-Ser25Glu as a ‘true’
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phospho-mimicking mutant (Fig. S1). By contrast, the
monoclonal antibody against total AnxA2 detects all
forms of AnxA2, including the wild-type AnxA2 and
mutated Ser25 variants (Fig. S1), corroborating its use
as a general tool. The 39 kDa (36 kDa by SDS/PAGE
[2]) form of AnxA2 is mainly enriched in the cytoskele-
tal fraction of PC12 cells (Fig. 1, lane 4), as previously
reported for Krebs II, L-929 and MPC-11 cells [28].
Thus, total AnxA2 is mainly found as a nonmodified
39 kDa monomeric form (Fig. 1). However, longer
exposure of the blots rendered the high-molecular-
mass AnxA2 bands more visible (results not shown),
indicating that the high-molecular-mass forms of
pSer25AnxA2 constitute only a minor fraction of total
AnxA2.
According to the results, pSer25AnxA2 is enriched
in the nuclear fraction (Fig. 1, lane 7). Moreover,
smaller amounts of the protein are present in the
cytoskeletal and ER fractions (Fig. 1, lanes 4 and 5
respectively). Thus, the subcellular distributions of
pSer25AnxA2 and the main form of AnxA2 are clearly
distinct. We expected to find pSer25AnxA2 as a
monomer of about 39 kDa. However, Fig. 1 shows
that the phosphorylated protein is almost exclusively
present in cells as high-molecular-mass forms, indicat-
ing that it could be subjected to ubiquitination [25]
and/or sumoylation, as well [38]. As ubiquitination is
involved in the association of AnxA2 with the
cytoskeleton, it was not surprising to find the phos-
phorylated, high-molecular-mass forms of AnxA2 in
the cytoskeletal fraction (Fig. 1, lane 4). However,
tubulin is also readily detectable in the nuclear fraction
(Fig. 1, lane 7), indicating that this fraction also con-
tains cytoskeletal elements, possibly due to the inti-
mate association of the centrosome with the nuclear
envelope (NE) [39].
The enrichment of fibrillarin in the nuclear fraction
shows that this fraction is enriched in nucleoplasmic
components (Fig. 1). However, the additional presence
of tubulin, the signal peptidase complex (SPC) and
complex II markers (Fig. 1) indicate that it also
contains perinuclear ER membranes, which are
in continuity with the NE, as well as the cytoskeletal
and/or centrosomal microtubuli and mitochondria.
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Fig. 1. Detection of pSer25AnxA2 in subcellular fractions derived from PC12 cells. Proteins (100 lg) from the cytoplasm (lane 1), the
cytoplasm devoid of mitochondria (-mit; lane 2), the cytosol (lane 3), the cytoskeleton (lane 4), ER (lane 5), mitochondria (lane 6), the nuclear
fraction (lane 7) and EGTA-released ECM (lane 8) were separated by 10% SDS/PAGE and subjected to western blot analysis. The blots
were probed with antibodies against pSer25AnxA2 and total AnxA2, as indicated. Antibodies against compartmental markers, namely the
cytoplasm (tubulin; 55 kDa), ER (SPC; 25 kDa), nucleus (fibrillarin; 35 kDa) and mitochondria (complex II; 70 kDa) were also employed as
indicated. The blot probed against pSer25AnxA2 was reprobed against fibrillarin, while the blot probed against AnxA2 was reprobed against
SPC. Only 25 lg of protein from the mitochondrial fraction was used for western blot analysis of tubulin and complex II on two different
membranes. Detection of the immunoreactive protein bands was performed using the ChemiDocTM XRS+ molecular imager after incubation
with HRP-conjugated secondary antibodies and enhanced chemiluminescence (ECL) reagent. The methods (A–D) used to generate the
different fractions are indicated above the western blots and described in the Methods section. The arrowheads to the left indicate the
protein molecular mass standards.
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Mitochondria have been shown to closely associate
with the NE [40], possibly providing the energy needed
for nuclear trafficking. We have previously shown that
glyceraldehyde 3-phosphate dehydrogenase (GAPDH)
and topoisomerase solely distribute to the cytoplasmic
and nuclear fractions respectively [41].
To gain further insight, the nuclear fraction (Fig. 1,
lane 7) was further fractionated into the nucleoplasm
and the perinuclear membrane fraction, which associ-
ates with cytoskeletal proteins/filaments [42]. This
analysis revealed that pSer25AnxA2 is absent from the
nucleoplasm (Fig. 2A, lane 1), but enriched in the
membrane fraction (Fig. 2A, lane 2), in agreement
with its presence in the ER fraction (Fig. 1, lane 5).
Our previous results showing that transfected AnxA2-
Ser25Glu-GFP and pSer25AnxA2 do not localise to
the nucleus [16] corroborate this conclusion. The
39 kDa form of AnxA2 is present both in the nucleo-
plasm and the NE (Fig. 2A, lanes 1 and 2). Although
fibrillarin, a nuclear marker, is detectable in both the
nucleoplasmic and membrane fractions, the absence of
tubulin and SPC from the former suggests that the
subfractionation of the nuclear fraction was successful
(Fig. 2A). The presence of fibrillarin in the NE frac-
tion could reflect its shuttling between the nucleus and
the cytoplasm [43]. Thus, in conclusion, the nuclear
fraction includes the NE, perinuclear ER membranes
and the nucleoplasm. Furthermore, pSer25AnxA2 is
enriched in perinuclear membranes as high-molecular-
mass forms.
Effect of PKC inhibitor on the perinuclear
localisation of pSer25AnxA2
To confirm the role of Ser25 phosphorylation in the
generation of the high-molecular-mass forms of
AnxA2, PC12 cells were treated with myr-w-PKC,
which by inhibiting protein phosphorylation by PKC
could influence the level of pSer25AnxA2. As
expected, the PKC inhibitor decreased the level of
pSer25AnxA2 in the nuclear fraction, which includes
the NE and associated perinuclear ER, as well as the
cytoplasm (Fig. 2B, compare lanes 3 and 4 and lanes 1
and 2, respectively). Besides indicating that myr-w-
PKC is a highly potent inhibitor of Ser25 phosphory-
lation of AnxA2, these results also verify that AnxA2
is a PKC substrate [10]. The cytoplasmic levels of the
39 kDa form of total AnxA2 in control and PKC inhi-
bitor-treated (Fig. 2B, lanes 1 and 2 respectively) PC12
cells are very similar. However, the level of the 39 kDa
form of total AnxA2 in the nuclear fraction decreases
dramatically in response to the inhibitor, while the
level of tubulin does not (Fig. 2B, lane 4). Confocal
microscopy showed that the PKC inhibitor leads to a
cortical enrichment of total AnxA2 at the expense of
its presence around the nucleus (Fig. 3C), corroborat-
ing the idea that Ser25 phosphorylation is a signal for
perinuclear targeting of AnxA2, possibly in the combi-
nation with ubiquitination and/or sumoylation. No
pSer25AnxA2 could be detected by confocal micro-
scopy when cells had been treated with the PKC inhi-
bitor (results not shown). Inhibition of PKC also
decreases the amount of tubulin in the cytoplasmic
fraction (Fig. 2B, lane 2), possibly due to a collapse of
the microtubule network, or the entire cytoskeleton.
Namely, PKC is known to regulate the dynamics of
the actin cytoskeleton [44] and PKC-mediated phos-
phorylation of a-tubulin is involved in cell motility
and regulation of the length of microtubules [45]. By
contrast, the level of (GAPDH) in the cytoplasmic
fraction was not affected by the treatment (Fig. 2B,
compare lanes 1 and 2). In conclusion, inhibition of
PKC inhibits perinuclear targeting of AnxA2.
pSer25AnxA2 and pTyr23AnxA2 show distinct
localisations
As subcellular fractionation only provides information
about the relative enrichment of specific components,
we next employed confocal microscopy to examine the
subcellular localisation of pSer25AnxA2. Strikingly,
pSer25AnxA2 was localised to punctate structures of
variable size around the nucleus. Many of the puncta
were found to closely associate with the NE, but many
were also localised at a distance from the nucleus
(Fig. 3). These results are compatible with our cell frac-
tionation data (Figs 1 and 2), suggesting that pSer25-
AnxA2 associates with cytoskeletal elements linked to
ER membranes that are in continuity with the NE. Dual
imaging further showed that Tyr23-phosphorylated
AnxA2 (pTyr23AnxA2) is enriched in the nucleus
(Fig. 3), showing that its subcellular distribution differs
from that of pSer25AnxA2. Thus, the two phosphory-
lated forms of AnxA2 are most likely functionally dis-
tinct [41]. Moreover, these data are in agreement with
the finding that the two phosphorylation events at
Ser25 and Tyr23 of AnxA2 are mutually exclusive [24].
In conclusion, pSer25AnxA2 shows a distinct subcellu-
lar localisation different from that of pTyr23AnxA2.
pSer25AnxA2 associates with perinuclear
nonpolysomal mRNP complexes and is
ubiquitinated
In vitro studies have shown that phosphorylation of
Ser25 increases the direct association of AnxA2 with
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mRNA [16], but the in vivo relevance of this finding
has not been previously addressed. Therefore, the
nuclear fraction (including NE) enriched in pSer25-
AnxA2 (Fig. 1, lane 7) was further subfractionated
into the corresponding polysomal and nonpolysomal
populations containing translationally active and inac-
tive mRNAs respectively (Fig. 4A,B). The nuclear
polysomal fraction contains no AnxA2 and only negli-
gible amounts of the high-molecular-mass bands of
pSer25AnxA2 (Fig. 4B, lane 5) associated with poly
(A)-containing mRNAs (Fig. 4B, lane 6), in accor-
dance with previous results showing that the 39 kDa
form of AnxA2 associates with cytoskeleton-bound
polysomes [28]. This indicates that pSer25AnxA2 is
not involved in active mRNA translation in the cyto-
plasmic (results not shown) or NE-associated poly-
somes. By contrast, pSer25AnxA2 and S6 kinase are
enriched in the oligo(dT)-isolated nonpolysomal
mRNP complexes, as compared to the starting fraction
(Fig. 4B, compare lanes 2 and 4), while S6, a marker
of small ribosomal subunits, is enriched in the nuclear
polysomal pellet (Fig. 4B, lane 5). This indicates the
specificity of the interaction of pSer25AnxA2 with
nonpolysomal, NE-associated mRNP complexes pre-
sent in the nuclear fraction (Fig. 2). Thus, pSer25-
AnxA2 could be involved in mRNA transport and/or
sequestering of inactive mRNAs in mRNP complexes,
most likely in P-bodies and/or stress granules [46,47].
The finding that AnxA2 binds to the localisation signal
in the 30UTR of c-myc mRNA [30], which targets the
mRNA to the perinuclear region for subsequent trans-
lation [36], is consistent with this idea.
To show that the high-molecular-mass forms of
AnxA2 associate not only with the mRNP complexes
present in the nuclear fraction but also with specific
mRNPs in general, and are ubiquitinated, we used still
another approach taking advantage of the fact that
AnxA2 binds to its cognate mRNA [31]. In vitro tran-
scribed and polyadenylated full-length anxA2 mRNA
coupled to oligo(dT)-magnetic beads was used as a ‘bait’
pSer25AnxA2 pTyr23AnxA2 Overlay
DAPI
Fig. 3. pSer25AnxA2 and pTyr23AnxA2 display distinct subcellular distributions in PC12 cells. Immunofluorescence double-staining was
carried out using rabbit polyclonal antibodies against pSer25AnxA2 (red) and mouse monoclonal antibodies against pTyr23AnxA2 (green),
followed by secondary anti-rabbit and anti-mouse antibodies coupled to Alexa 594 (red fluorescence) and fluorescein isothiocyanate (FITC)
(green fluorescence) respectively. DNA staining with 40,6-diamidino-2-phenylindole (blue fluorescence) was used to visualise the nucleus.
Note that pTyr23AnxA2 (green) is present as a punctate pattern in both the nucleus and the cytoplasm, while pSer25AnxA2 (red) is
predominantly found in large punctate structures in the cytoplasm and next to the NE (arrows). Scale bar is 10 lm.
Fig. 2. Distribution of pSer25AnxA2 in nuclear subfractions of PC12 cells (A). Proteins (100 lg) from the nucleoplasm (lane 1) and NE (lane
2) fractions were separated by 10% SDS/PAGE and subjected to western blot analysis. The blot was probed with antibodies against
pSer25AnxA2, total AnxA2, tubulin, SPC and fibrillarin, as indicated. myr-w-PKC inhibits Ser25 phosphorylation of AnxA2 and shifts the
localisation of AnxA2 from the perinuclear to the cortical region of PC12 cells (B, C). Proteins (100 lg) from the cytoplasmic (lanes 1 and 2)
and nuclear (lanes 3 and 4) fractions prepared from myr-w-PKC-treated (+; lanes 2 and 4) and control (; lanes 1 and 3) cells were separated
by 10% SDS/PAGE and subjected to western blot analysis (B). The blots were probed with antibodies against pSer25AnxA2, total AnxA2,
tubulin and GAPDH, as indicated. Detection of the resulting protein bands (A, B) was performed using the ChemiDocTM XRS+ molecular
imager after incubation with HRP-conjugated secondary antibodies and ECL reagent. The arrows to the left indicate the protein molecular
mass standards (nd, not determined). Immunofluorescence staining of control and myr-w-PKC-treated cells, as indicated, was carried out
using rabbit polyclonal antibodies against AnxA2 (green) (C). DNA staining with DAPI (blue fluorescence) was included to visualise the
nucleus. Scale bar is 10 lm. The insets show higher magnification of the indicated areas in the images shown to the right in Panel (C).
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Fig. 4. pSer25AnxA2 and ubiquitinated high-molecular-mass forms of AnxA2 associate with translationally inactive mRNP complexes. (A, B)
High-molecular-mass forms of pSer25AnxA2 is present in oligo(dT)-purified nonpolysomal mRNP complexes in PC12 cells. (A) Schematic
representation of the method used in (B) with reference to the individual lanes in (B). (B) Samples (100 lg of protein) were prepared from
the following fractions: nucleus (lane 1), supernatant (lane 2) and polysome-containing pellet (lane 5; derived from the nuclear fraction after
centrifugation for 2 h 100 000 g through a 1 M sucrose cushion), non-oligo(dT)-bound supernatant (lane 3), oligo(dT)-bound supernatant (lane
4), and oligo(dT)-bound pellet (lane 6), as indicated above the western blot. The proteins were separated by 10% SDS/PAGE and subjected
to western blot analysis. The blots were probed with antibodies against pSer25AnxA2, total AnxA2, tubulin, SPC, S6 kinase and the
ribosomal protein S6, as indicated. Detection of the resulting protein bands was performed by the ChemiDocTM XRS+ molecular imager after
incubation with HRP-conjugated secondary antibodies and ECL reagent. The arrowheads to the left indicate the protein molecular mass
standards. (C, D) High-molecular-mass forms of AnxA2 in mRNP complexes affinity-purified via binding to anxA2 mRNA represent
ubiquitinated forms of the protein. (C) Schematic overview of the method used in (D) with reference to the individual lanes in (D). Proteins
(100 lg) present in the total cytoskeletal fraction derived from NGF-stimulated PC12 cells (lanes 1 and 5), the unbound fraction (lanes 2 and
6) and AnxA2 IP proteins from the affinity-purified mRNP complexes derived from the cytoskeletal fraction (lanes 3 and 7), were subjected
to 10% SDS/PAGE and immunoblot analysis using monoclonal antibodies against AnxA2 (lanes 1–4) or Ub (lane 5–7). The bands
representing ubiquitinated AnxA2 are indicated by the upper bracket to the right. Lane 4 represents a negative control, showing the binding
of cytoskeleton-associated proteins to anxA2 mRNA coupled to oligo(dT) magnetic beads in the presence of RNase, followed by IP using
monoclonal AnxA2 antibodies. The molecular mass markers are indicated to the left and the IgG heavy (Hc; arrowhead) and light (Lc; lower
bracket) chains to the right.
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to capture proteins in the cytoskeletal fraction of PC12
cells that had been stimulated with nerve growth factor
(NGF) to increase the expression of AnxA2 [48]. Subse-
quently, these mRNP complexes were subjected to
AnxA2 immunoprecipitation (IP) to recover AnxA2
associated with mRNP complexes (Fig. 4C). Immuno-
blot analysis of the mRNP complexes isolated by mono-
clonal antibodies against AnxA2 showed specific
enrichment of the high-molecular-mass forms of the pro-
tein, as compared to the starting cytoskeletal fraction
(Fig. 4D, compare lanes 1 and 3). Using monoclonal
ubiquitin (Ub) antibodies, the high-molecular-mass
bands could be identified as ubiquitinated forms of
AnxA2 (Fig. 4D, lane 7). Whether ubiquitination targets
AnxA2 for proteasomal degradation remains a subject of
further studies, as our previous in vitro experiments failed
to resolve this question [25]. The protein has been
reported to have a relatively long half-life (~ 15 h) and to
be degraded by chaperone-mediated autophagy [49],
arguing against this possibility.
To gain further insight into the functional role
of the pSer25AnxA2-containing nonpolysomal mRNP
complexes, double-localisation studies with markers of
P-bodies (GW182), stress granules (TIA-1) and neu-
ronal granules (HuD), which all contain translationally
inactive mRNAs, were performed. Of the three marker
proteins, pSer25AnxA2 only showed partial colocalisa-
tion with the P-body marker GW182 (Fig. 5, arrows;
see also intensity profiles). Arsenite treatment did not
increase its colocalisation with any of the markers (data
not shown). These studies further suggest that pSer25-
AnxA2 associates mainly with actively transported
mRNP complexes, rather than contributing to the
sequestration of the associated mRNAs in or next to
P-bodies, either for transient storage or degradation.
Previous results showing that markers of P-bodies and
transported RNPs do not colocalise in the dendrites of
mature hippocampal neurons lead to the proposal that
dendritic mRNAs could be stored in P-bodies and sub-
sequently released and translated only after activation
of the synapses [50]. In conclusion, ubiquitinated and
pSer25AnxA2 is a component of nonpolysomal mRNP
complexes that, based on confocal microscopy, appear








































Fig. 5. pSer25AnxA2 partially colocalises with the P-body marker GW182. PC12 cells were double-stained for immunofluorescence using
mono- and polyclonal antibodies against GW182 (green) and pSer25AnxA2 (red) respectively. The insets in the merged confocal image to
the left – including DAPI staining (blue) to highlight the nuclei – show higher magnifications of the regions, denoted in 3 and 4, to illustrate
the partial colocalisation of pSer25AnxA2 and GW182. Scale bar: 10 lm. The fluorescence intensity profiles (from left to right) of the two
proteins correspond to the cross-sections, denoted 1 and 2, shown in the insert in the upper right corner of the merged image.
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High-molecular-mass forms of pSer25AnxA2 are
modified by Ub and/or SUMO1
We showed that pSer25AnxA2 in mRNP complexes is
ubiquitinated, but could not rule out that sumoylation
is involved, although this modification appears to be
particularly relevant for nuclear import [51]. Thus, IP of
AnxA2, Ub or SUMO1 in the nuclear fraction was per-
formed (Fig. 6). It is evident from the immunoblot that
pSer25AnxA2 is both ubiquitinated and sumoylated.
There are several examples of proteins that are both
ubiquitinated and sumoylated [52]. For example, the
functions of the PML protein are regulated by phospho-
rylation, ubiquitination and sumoylation either in com-
binations or alone (discussed in [52]). We previously
observed that pTyr23AnxA2 is also ubiquitinated [41],
although the pattern of its high-molecular-mass forms
differs from that of the pSer25AnxA2 (Fig. 6) [41]. Fur-
thermore, the two phosphorylated forms of the protein
are localised to distinct cellular compartments (Fig. 3).
Thus, the post-translational regulation of AnxA2 is
highly complex and may involve cross-talk between its
two termini, as shown for AnxA1 [53]. Further in vitro
investigations are hampered by the fact that the E3
ligase for ubiquitination of AnxA2 is unknown. How-
ever, it is clear that pSer25AnxA2 shows a more distinct
pattern of high-molecular-mass forms than pTyr23-
AnxA2 and appears to be ubiquitinated and/or sumoy-
lated. The ladder of high-molecular-mass forms of
AnxA2 shown in Fig. 4D, lane 7 is more pronounced
than that seen in Fig. 6, lane 4. Namely, in the first case,
AnxA2 was immunoprecipitated from purified mRNP
complexes formed by its cognate mRNA, while in the
latter case, AnxA2 was immunoprecipitated from a
subcellular fraction containing not only proteins present
in mRNP complexes but also residing in other cellular
structures. Overexposure of the blot presented in Fig. 6
revealed the presence of the high-molecular-mass forms
of Ub-conjugated AnxA2 (lane 4). Thus, these results
support the conclusion that the ubiquitinated (and/or
sumoylated forms) of AnxA2 associate with mRNP
complexes.
The presence of AnxA2 in ubiquitinated forms raises
the possibility that phosphorylation of Ser25 triggers
this modification, as shown for c-Myc [54]. We have
not been able to in vitro ubiquitinate AnxA2 directly
as the required E3 ligase is unknown. To circumvent
the problems in using an in vitro pSer25AnxA2 in
incubations with a lysate containing both kinases and
phosphatases, the phospho-mimicking form of AnxA2
was employed. Thus, experiments where a lysate from
PC12 cells was used to in vitro ubiquitinate and/or
sumoylate recombinant wt AnxA2 and the phospho-
mimicking form, AnxA2-Ser25Glu, resulted in more
high-molecular-mass AnxA2 forms after the 1-h incu-
bation in the latter case (Fig. 7), suggesting that Ser25
phosphorylation could be a trigger for ubiquitination
(and/or sumoylation).
Taking into account previous studies implicating
ubiquitination in the quality control of nuclear export
of mRNAs in yeast [55], together with the finding that
AnxA2 binds to the localisation element of the 30UTR
of c-myc mRNA [30], localised to the perinuclear
region [36], our present results raise the interesting
possibility that ubiquitination (and/or sumoylation) of
AnxA2 provides a candidate mechanism to sequester
mRNAs in an inactive and transport competent form.
Probed with: pSer25AnxA2 pTyr23AnxA2
1 87632















Fig. 6. pSer25AnxA2 is ubiquitinated and sumoylated, but shows a different high-molecular-mass pattern than pTyr23AnxA2. Proteins
(100 lg) in the cytoplasmic (lanes 1 and 8) and nuclear (lanes 2 and 9) fractions (1/6 input) as well as IPs of AnxA2 (lanes 3–5 and 10), Ub
(lane 6) or SUMO1 (lane 7) from the nuclear fraction of PC12 cells were subjected to 10% SDS/PAGE and western blot analysis using
antibodies against pSer25AnxA2 or pTyr23Anxa2, as indicated. Note that the secondary anti-mouse HRP-conjugated antibody obtained from
Jackson Immuno-Research (205-032-176) is light chain specific and also note that the blots probed with the polyclonal anti-pSer25AnxA2
shows no light chain as the antibodies against AnxA2, Ub and SUMO1 are all mouse monoclonal antibodies. The immunoreactive protein
bands on the membrane were visualised using ECL reagents.
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This PTM, together with Ser25 phosphorylation of
AnxA2 could target these mRNP complexes to specific
cellular sites, in particular to the perinuclear region.
Materials and methods
Cell culture and drug treatments
Rat pheochromocytoma (PC12) cells derived from adrenal
medulla [56] were maintained as described previously [16].
For the fractionation of polysomes and mRNP complexes,
the cells were treated for 15 min with 100 lgmL1 cyclo-
heximide (CHX) prior to harvest. Subsequently, the cells
were rinsed twice with PBS (0.14 M NaCl, 2.7 mM KCl,
14.5 mM Na2HPO4, 2.9 mM KH2PO4) and centrifuged for
5 min at 800 g before fractionation. Prior to the 30-min
treatment with 100 lM myr-w-PKC (Promega, Madison,
WI, USA), the cells were serum starved for 5 h in a med-
ium containing 1% horse serum and 0.5% fetal calf serum.
Isolation of subcellular fractions from PC12 cells
A whole PC12 cell lysate was obtained by incubation for
15 min in RIPA buffer (150 mM NaCl, 1% NP-40, 1%
sodium deoxycholate, 0.1% SDS, 25 mM Tris/HCl; pH 7.6)
supplemented with 2 mM EGTA and 19 protease inhibitor
cocktail (Roche, Mannheim, Germany; EDTA-free) and
centrifuged for 20 min at 12 000 g at 4 °C. The cytosolic,
cytoskeletal and membrane fractions of PC12 cells were iso-
lated essentially as described previously [57] (Method C in
Fig. 1). Essentially, PC12 cells from one large flask (7.5 mL
of medium supplemented with serum) were lysed for 10 min
on ice in 0.1 mL of 25 mM KCl buffer (25 mM KCl, 5 mM
MgSO4, 8.6% sucrose, 10 mM Triethanolamin; pH 7.4) with
0.075% Triton X-100, 19 protease inhibitor cocktail
(Roche; EDTA-free) and 200 lM orthovanadate before cen-
trifugation at 800 g for 10 min. The supernatant contained
the cytosol and some released membrane proteins. The pel-
let was washed once in 25 mM KCl buffer without detergent
and centrifuged at 800 g for 10 min at 4 °C. The resulting
pellet was resuspended in 0.1 mL of 130 mM KCl buffer
(130 mM KCl, 5 mM MgSO4, 8.6% sucrose, 10 mM Tri-
ethanolamin; pH 7.4) supplemented with protease inhibitors
and orthovanadate. The resuspension was incubated for
20 min at room temperature and centrifuged at 800 g for
10 min at 4 °C. The supernatant contained the cytoskeleton
fraction. The pellet was resuspended in 0.1 mL of 130 mM
KCl buffer supplemented with protease inhibitors, ortho-
vanadate and 0.25% Triton X-100 and 0.25% deoxycholate
and incubated for 10 min on ice before centrifugation at
800 g for 10 min at 4 °C. The supernatant contained mem-
brane-bound proteins (especially from the ER).
The isolation of cytoplasmic and nuclear fractions was car-
ried out according to the protocol provided in the ‘NE-
PER Nuclear and Cytoplasmic Extraction Reagents’ kit
(ThermoFisher Scientific, Rockford, IL, USA; Method A in
Fig. 1). The nuclear fraction was further fractionated into
nucleoplasmic and NE fractions using ultracentrifugation in
density gradients [58]. Polysomes were pelleted by ultracen-
trifugation for 2 h at 100 000 gav at 4 °C through a 35%
(1 M) sucrose cushion prepared in 10 mM Triethanolamine
(pH 7.4), 130 mM KCl, 5 mM MgSO4 and 70 lM CaCl2,
essentially as described earlier [59]. Nuclear polysomes were
released from membranes by the addition of 0.5% Triton X-
100 and 0.5% sodium deoxycholate prior to ultracentrifuga-
tion. Poly(A)-containing mRNAs of mRNP complexes in the
resulting supernatant above the sucrose cushion and the
polysomal pellet – after splitting of the ribosomes by incuba-
tion for 10 min with 50 mM EDTA on ice – were isolated by
using of magnetic oligo(dT) Dynabeads, essentially as
described by the manufacturer (ThermoFisher Scientific).
Further fractionation of the cytoplasm and harvesting of
mitochondria was carried out using the protocol (option A)
provided in the ‘Mitochondria Isolation Kit for Cultured
Cells’ (ThermoFisher Scientific; Method B in Fig. 1). To
obtain a mitochondrial fraction of higher purity, an addi-
tional centrifugation step (15 min at 3000 g) was included
as a minor modification in the protocol, prior to the collec-
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Fig. 7. Ser25 phosphorylation appears to trigger the formation of
high-molecular-mass forms of AnxA2. Recombinant wt His-AnxA2
(lane 1, 1 lg) and the phospho-mimicking His-AnxA2-Ser25Glu (lane
2, 1 lg) were bound to Ni2+-resin (lanes 4 and 5 respectively) and
incubated with PC12 total cell lysate for 1 h before elution with 250
imidazole buffer. 1.5 lg of the eluted wt His-AnxA2 (lane 4) and His-
AnxA2-Ser25Glu (lane 5) were loaded on the gel. As a control,
elution of proteins present in the PC12 cell lysate that may bind
unspecifically to the resin was also performed (lane 3). Proteins
were separated by 10% SDS/PAGE and subjected to western blot
analysis. The blots were probed with antibodies against AnxA2.
Detection of the resulting protein bands was performed using the
ChemiDocTM XRS+ molecular imager after incubation with HRP-
conjugated secondary antibodies and ECL reagent. The arrowheads
to the left indicate the protein molecular mass standards.
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Furthermore, after the first lysis step, the cells were homo-
genised with a small grinder to obtain a higher yield of
mitochondria.
Extracellular matrix proteins were released by incubation
for 10 min in 2 mM EGTA before centrifugation for 5 min
at 800 g (Method D in Fig. 1). Protease inhibitor cocktail
(Roche; EDTA-free) was present during all fractionations.
In vitro transcription and polyadenylation of
anxA2 mRNA followed by binding to oligo(dT)
magnetic beads and binding to cytoskeletal
proteins
Bovine anxA2 cDNA was subcloned into the pGEM3Zf(+)
vector and linearised by BamHI. Subsequently, the full-
length anxA2 mRNA containing both UTRs was in vitro
transcribed as described in the manual for the RibomaxTM
Large Scale RNA Production System-T7 (Promega). Pre-
cipitated transcribed mRNA was dissolved in poly-adenyla-
tion (polyA) buffer (50 mM Tris/HCl of pH 7.9, 250 mM
NaCl, 10 mM MgCl2 and 2.5 mM MnCl2), and its purity
and integrity was verified by agarose gel electrophoresis.
Polyadenylation was performed for 30 min at 37 °C in the
presence of 0.03 UlL1 poly(A) polymerase (Invitrogen;
ThermoFisher Scientific, Rockford, IL, USA), 0.5 mgmL1
bovine serum albumin (BSA) and 0.25 mM ATP. The cou-
pling of poly(A) mRNAs to the oligo(dT) magnetic beads
(Dynal; ThermoFisher Scientific, Rockford, IL, USA) was
performed essentially as described by the manufacturer,
with minor modifications. Accordingly, 50 lg of the poly
(A)-containing anxA2 mRNA was diluted in 200 lL bind-
ing buffer [20 mM Tris/HCl (pH 7.2), 1 M LiCl, 1.25 mM
EDTA], followed by heating for 2 min at 65 °C and subse-
quent cooling on ice. After washing of the oligo(dT) mag-
netic beads with binding buffer, the mRNA sample was
annealed to the beads in 800 lL binding buffer and incu-
bated for 10 min at RT on a platform shaker, followed by
further incubation for 50 min at 4 °C. The anxA2 mRNA-
bound oligo(dT) beads were washed extensively with
10 mM Tris/HCl (pH 7.2), 0.15 M LiCl and 1 mM EDTA to
remove nonannealed mRNA.
The cytoskeletal fraction (~ 600 lg protein) of PC12 cells
was diluted 1 : 4 in RNA-binding buffer [10 mM Tri-
ethanolamine (pH 7.4), 50 mM NaCl, 1 mM DTT, 2 mM
MgSO4, 1 mM CaCl2] containing 1 mgmL1 yeast tRNA
and 0.4 UlL1 ribonuclease inhibitor (Fermentas, Thermo-
Fisher Scientific, Rockford, IL, USA). Subsequently, the
fractions were incubated for 60 min with the anxA2
mRNA-bound oligo(dT) magnetic beads at 4 °C on a plat-
form shaker. The beads were then washed three times with
tRNA-free RNA-binding buffer. Polyadenylated anxA2
mRNAs with bound proteins were eluted from the beads by
incubation for 10 min at 65 °C either in 60 lL elution buf-
fer (preheated at 65 °C), containing 0.1% SDS and 1 mM
DTT or in 10 mM Tris/HCl (pH 7.4). The elution step was
repeated once, and the mRNAs in the two combined frac-
tions were degraded by incubation with 0.3 lglL1 RNase
A for 5–10 min at 30 °C to facilitate the separation of pro-
teins by SDS/PAGE for immunoblot analyses.
Protein determination
The protein concentrations of the various subcellular frac-
tions were measured using the Bradford method [60].
SDS/PAGE, western blot analysis and
immunoprecipitation
Proteins were separated by 10% SDS/PAGE and blotted
onto nitrocellulose membranes ON at 150 Vh. The mem-
branes were incubated with the different primary antibodies
and, subsequently, the corresponding horseradish peroxidase
(HRP)-conjugated secondary antibodies [goat anti-rabbit
(170-6515; BioRad, Hercules, CA, USA) or goat anti-mouse
(170-6516; BioRad)] to detect the following proteins in the
different fractions: pSer25AnxA2 (OAAF00618; Aviva Sys-
tems Biology, San Diego, CA, USA; 1 : 2000 dilution), total
AnxA2 (610069; BD Biosciences, San Jose, CA, USA;
1 : 1000 dilution), tubulin (A01410-40; Genscript, Piscat-
away, NJ, USA; 1 : 6000 dilution), signal peptidase complex
(SPC; 1 : 2000 dilution; a generous gift from S. High, Univer-
sity of Manchester, UK), Complex II (2E3GC12FB2AE2;
Invitrogen, ThermoFisher Scientific; 1 : 2000 dilution), fibril-
larin (C13C3; Cell Signaling, Danvers, MA, USA; 1 : 2000
dilution), S6 kinase (sc-8418; Santa Cruz Biotechnology, Dal-
las, TX, USA; 1 : 100 dilution), S6 (9HCLC; Invitrogen,
ThermoFisher Scientific; dilution 1 : 250), and GAPDH
(ab9485; Abcam, Cambridge, UK; dilution 1 : 2000), as indi-
cated in the figure legends. Polyclonal AnxA2 antibodies, a
generous gift from Jesus Ayala-Sanmartin (Universite Pierre
et Marie Curie, Paris, France), were used at a 1 : 5000 dilu-
tion. Antibody binding was detected using enhanced chemilu-
minescence (ECL; Advansta, Menlo Park, CA, USA).
Six hundred microgram of proteins was IP in NET buf-
fer (50 mM Tris/HCl of pH 7.4, 150 mM KCl, 0.05% Triton
X-100, 0.2 mM CaCl2 and 2 mM N-ethylmaleimide) using
2.75 lg monoclonal AnxA2 (610069; BD Biosciences), Ub
(131600; Invitrogen, ThermoFisher Scientific) or SUMO1
(sc-5308; Santa Cruz Biotechnology) antibodies coupled to
protein G-Sepharose (Sigma-Aldrich, St. Louis, MO, USA)
essentially as previously described [31]. Ribolock (Thermo-
Fisher Scientific) RNase inhibitor was present when using
mRNP complexes for IP. Normal mouse IgG (sc-2025;
Santa Cruz Biotechnology) coupled to protein G-Sepharose
was used for preclearance.
Confocal imaging
PC12 cells were fixed, permeabilised and blocked as
described previously [16,61], prior to staining with primary
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antibodies against AnxA2 (polyclonal; ab41803; Abcam,
1 : 250 dilution), pTyr23AnxA2 (monoclonal; sc-135753;
Santa Cruz Biotechnologies; 1 : 20 dilution), pSer25AnxA2
(polyclonal; OAAF00618; Aviva Systems Biology; 1 : 250
dilution) and GW182 (monoclonal; sc-56314; Santa Cruz
Biotechnologies; 1 : 10 dilution). The bound primary anti-
bodies were detected using appropriate DyLight 488- or
DyLight 594-conjugated goat anti-rabbit or -mouse Fab2
fragments (Jackson ImmunoResearch Laboratories, West
Grove, PA, USA; 1 : 50 dilution).
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